Loading clinical trials...

Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration | Clinical Trials | Clareo Health

UNKNOWNNA

Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration

Randomized Study Evaluating Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration

NCT05884905•Mahidol University

View on ClinicalTrials.gov

Summary

The aim of the study is to evaluate safety of short hydration with cisplatin administration. The main outcome is renal dysfunction following cisplatin use with short hydration protocol. Another group of patients received conventional hydration is the historical control for comparison (Randomized phase II design with a reference standard treatment control arm)

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cancer patient who has plan to receive first cycle of cisplatin \>= 60 mg/m2
•Normal serum creatinine and creatinine clearance \>= 50 ml/min
•Age \< 75 years old
•Serum albumin \>= 3 g/dl
•Plan to receive optimal antiemetic regimen consisting of olanzapine or neurokinase 1 receptor antagonist

Exclusion Criteria

•The patient who receives other chemotherapy with adminstration volume higher than 500 ml
•Prior heart failure or known left ventricular ejection fraction \> 50%
•Prior renal dysfunction within 3 months
•Uncontrolled renal disease
•current use of diuretic or non-steroidal anti-inflammatory drug (NSAIDs) or starting angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blockade (ARB) within 3 months

Locations (1)

Faculty of Medicine Siriraj Hospital

Bangkok, Thailand

Key Dates

Start Date

March 7, 2023

Primary Completion Date

January 7, 2025

Completion Date

March 7, 2025

Last Updated

June 1, 2023

Enrollment

100

ESTIMATED participants

Conditions

Renal InsufficiencyCis-Platinum Nephropathy

Interventions

short hydration

PROCEDURE

conventional hydration

PROCEDURE

Contacts

Suthinee Ithimakin, MD

CONTACT

+66898127440 aesi105@yahoo.co.th

Product Surveillance Registry

NCT01524276

Cardiac Rhythm DisordersUrological Disorders+14 more

View study

RECRUITINGPHASE1

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency

NCT07262333

Renal Insufficiency Chronic

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 1, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety of Short Hydration Method for Cisplatin Administration Compared With Conventional Hydration

Inclusion Criteria

Exclusion Criteria

Product Surveillance Registry

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency

Evaluation of Children With Endocrine and Metabolic-Related Conditions

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

Amino Acid Loss During Continuous Renal Replacement Therapy

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial